Literature DB >> 26685721

Rapid skin repigmentation on oral ruxolitinib in a patient with coexistent vitiligo and alopecia areata (AA).

John E Harris1, Mehdi Rashighi2, Nhan Nguyen3, Ali Jabbari3, Grace Ulerio3, Raphael Clynes3, Angela M Christiano4, Julian Mackay-Wiggan5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2015        PMID： 26685721      PMCID： PMC4718770          DOI： 10.1016/j.jaad.2015.09.073

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN： 0190-9622            Impact factor:   11.527


× No keyword cloud information.
  5 in total

Review 1.  Janus kinase inhibitors for the treatment of myeloproliferative neoplasias and beyond.

Authors:  Alfonso Quintás-Cardama; Hagop Kantarjian; Jorge Cortes; Srdan Verstovsek
Journal:  Nat Rev Drug Discov       Date:  2011-02       Impact factor: 84.694

2.  Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition.

Authors:  Luzhou Xing; Zhenpeng Dai; Ali Jabbari; Jane E Cerise; Claire A Higgins; Weijuan Gong; Annemieke de Jong; Sivan Harel; Gina M DeStefano; Lisa Rothman; Pallavi Singh; Lynn Petukhova; Julian Mackay-Wiggan; Angela M Christiano; Raphael Clynes
Journal:  Nat Med       Date:  2014-08-17       Impact factor: 53.440

3.  Ruxolitinib versus standard therapy for the treatment of polycythemia vera.

Authors:  Alessandro M Vannucchi; Jean Jacques Kiladjian; Martin Griesshammer; Tamas Masszi; Simon Durrant; Francesco Passamonti; Claire N Harrison; Fabrizio Pane; Pierre Zachee; Ruben Mesa; Shui He; Mark M Jones; William Garrett; Jingjin Li; Ulrich Pirron; Dany Habr; Srdan Verstovsek
Journal:  N Engl J Med       Date:  2015-01-29       Impact factor: 91.245

4.  Tofacitinib Citrate for the Treatment of Vitiligo: A Pathogenesis-Directed Therapy.

Authors:  Brittany G Craiglow; Brett A King
Journal:  JAMA Dermatol       Date:  2015-10       Impact factor: 10.282

5.  CXCL10 is critical for the progression and maintenance of depigmentation in a mouse model of vitiligo.

Authors:  Mehdi Rashighi; Priti Agarwal; Jillian M Richmond; Tajie H Harris; Karen Dresser; Ming-Wan Su; Youwen Zhou; April Deng; Christopher A Hunter; Andrew D Luster; John E Harris
Journal:  Sci Transl Med       Date:  2014-02-12       Impact factor: 17.956
  5 in total
  43 in total

1.  Interfering with the IFN-γ/CXCL10 pathway to develop new targeted treatments for vitiligo.

Authors:  Mehdi Rashighi; John E Harris
Journal:  Ann Transl Med       Date:  2015-12

Review 2.  Vitiligo: Focus on Clinical Aspects, Immunopathogenesis, and Therapy.

Authors:  Katia Boniface; Julien Seneschal; Mauro Picardo; Alain Taïeb
Journal:  Clin Rev Allergy Immunol       Date:  2018-02       Impact factor: 8.667

Review 3.  Vitiligo Pathogenesis and Emerging Treatments.

Authors:  Mehdi Rashighi; John E Harris
Journal:  Dermatol Clin       Date:  2017-04       Impact factor: 3.478

Review 4.  T-cell positioning by chemokines in autoimmune skin diseases.

Authors:  Jillian M Richmond; James P Strassner; Kingsley I Essien; John E Harris
Journal:  Immunol Rev       Date:  2019-05       Impact factor: 12.988

Review 5.  Pigmentary changes in patients treated with targeted anticancer agents: A systematic review and meta-analysis.

Authors:  Julia Dai; Viswanath R Belum; Shenhong Wu; Vincent Sibaud; Mario E Lacouture
Journal:  J Am Acad Dermatol       Date:  2017-09-14       Impact factor: 11.527

Review 6.  Advances in Vitiligo: An Update on Medical and Surgical Treatments.

Authors:  Alexander B Dillon; Andrew Sideris; Ali Hadi; Nada Elbuluk
Journal:  J Clin Aesthet Dermatol       Date:  2017-01-01

Review 7.  The Role of Memory CD8+ T Cells in Vitiligo.

Authors:  Rebecca L Riding; John E Harris
Journal:  J Immunol       Date:  2019-07-01       Impact factor: 5.422

8.  Repigmentation in vitiligo using the Janus kinase inhibitor tofacitinib may require concomitant light exposure.

Authors:  Lucy Y Liu; James P Strassner; Maggi A Refat; John E Harris; Brett A King
Journal:  J Am Acad Dermatol       Date:  2017-08-18       Impact factor: 11.527

9.  Oral ruxolitinib induces hair regrowth in patients with moderate-to-severe alopecia areata.

Authors:  Julian Mackay-Wiggan; Ali Jabbari; Nhan Nguyen; Jane E Cerise; Charlotte Clark; Grace Ulerio; Megan Furniss; Roger Vaughan; Angela M Christiano; Raphael Clynes
Journal:  JCI Insight       Date:  2016-09-22

Review 10.  Understanding autoimmunity of vitiligo and alopecia areata.

Authors:  Jillian F Rork; Mehdi Rashighi; John E Harris
Journal:  Curr Opin Pediatr       Date:  2016-08       Impact factor: 2.856
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.